UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 39

Sortiert nach

ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer

Annals of oncology, 2023-08, Vol.34 (8), p.645-659

2023

Volltextzugriff (PDF)

Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer

Annals of oncology, 2012-05, Vol.23 (5), p.1156-1164

2012

Volltextzugriff (PDF)

Clinical impact of circulating tumor RAS and BRAF mutation dynamics in metastatic colorectal cancer patients treated with first-line chemotherapy plus anti-EGFR therapy: Combined analysis of two prospective clinical trials

Annals of oncology, 2018-10, Vol.29 Suppl 8, p.viii182

2018

Volltextzugriff (PDF)

MiR-29c downregulation contributes to metastatic progression in colorectal cancer

Annals of oncology, 2015-10, Vol.26 (10), p.2199-2200

2015

Volltextzugriff (PDF)

SET overexpression promotes colorectal cancer progression and determines poor outcome in patients with localized disease

Annals of oncology, 2018-10, Vol.29, p.viii24-viii24

2018

Volltextzugriff (PDF)

Prospective biomarker study in advanced RAS wild-type colorectal cancer: POSIBA trial

Annals of oncology, 2018-10, Vol.29 Suppl 8, p.viii164

2018

Volltextzugriff (PDF)

45P In silico transcriptomic mapping of Notch biological pathway in luminal breast cancer

Annals of oncology, 2022-10, Vol.33, p.S1397-S1397

2022

Volltextzugriff (PDF)

Comorbidities (CM) and potential impact in outcomes of advanced colorectal cancer patients (ACC) in Argentina: EVIREPRO real life program - Trial in progress

Annals of oncology, 2018-06, Vol.29, p.v82-v83

2018

Volltextzugriff (PDF)

Lack of efficiency of precision oncology with target-based investigational treatments for patients in early phase clinical trials based on pre-screened molecular alterations

Annals of oncology, 2018-10, Vol.29, p.viii650-viii650

2018

Volltextzugriff (PDF)

Involvement of miR-99a in resistance to chemotherapy in triple-negative breast cancer

Annals of oncology, 2018-09, Vol.29, p.vi32-vi32

2018

Volltextzugriff (PDF)

Role of miR-449 family on doxorubicin-based chemotherapy response in triple-negative breast cancer

Annals of oncology, 2018-09, Vol.29, p.vi25-vi25

2018

Volltextzugriff (PDF)

Micro-RNA 33b inhibits breast cancer migration and invasion through regulating epithelial-mesenchymal transition in HER2 positive breast cancer cell lines

Annals of oncology, 2017-10, Vol.28, p.vii19-vii20

2017

Volltextzugriff (PDF)

195P A prognostic signature based on two-miRNA and pathological data in early-stage HER2+ breast cancer patients

Annals of oncology, 2021-09, Vol.32, p.S442-S442

2021

Volltextzugriff (PDF)

Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxel

Annals of oncology, 2010-06, Vol.21 (6), p.1315-1322

2010

Volltextzugriff (PDF)

319P - The role of AXL as mechanism of resistance to trastuzumab and a prognostic factor in breast cancer HER2 positive: A translational approach

Annals of oncology, 2019-10, Vol.30, p.v110-v110

2019

Volltextzugriff (PDF)

The role of AXL as mechanism of resistance to trastuzumab and a prognostic factor in breast cancer HER2 positive: A translational approach

Annals of oncology, 2019-10, Vol.30, p.v110

2019

Volltextzugriff (PDF)

First prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis

Annals of oncology, 2017-09, Vol.28, p.v36-v36

2017

Volltextzugriff (PDF)

Prospective evaluation of BRAF, PI3K and PTEN as predictive and prognostic biomarkers in first-line advanced KRAS wild-type colorectal cancer treated with FOLFOX or FOLFIRI plus bi-weekly cetuximab. GEMCAD 10-02

Annals of oncology, 2016-10, Vol.27, p.vi178-vi178

2016

Volltextzugriff (PDF)

AXL as a potential primary and secondary trastuzumab resistance mechanism in breast cancer cells with HER2 overexpression

Annals of oncology, 2017-09, Vol.28, p.v4-v4

2017

Volltextzugriff (PDF)

A phase I study of sonidegib (S) in combination with docetaxel (D) in patients (pts) with triple negative (TN) advanced breast cancer (ABC): GEICAM/2012-12 (EDALINE study)

Annals of oncology, 2016-10, Vol.27, p.vi87-vi87

2016

Volltextzugriff (PDF)

MicroRNA-31 overexpression is able to predict pathological response and outcome in locally advanced rectal cancer

Annals of oncology, 2016-10, Vol.27, p.vi179-vi179

2016

Volltextzugriff (PDF)

A phase II trial of dasatinib (D) in combination with trastuzumab (T) and paclitaxel (P) in the first line treatment of HER2 positive metastatic breast cancer (MBC) patients (pts): GEICAM/2010-04

Annals of oncology, 2017-09, Vol.28, p.v75-v75

2017

Volltextzugriff (PDF)

Analysis of stroma and immune-related gene expression patterns during breast cancer (BC) progression

Annals of oncology, 2017-09, Vol.28, p.v597-v598

2017

Volltextzugriff (PDF)

Gestational breast cancer: distinctive molecular and clinico-epidemiological features. GEICAM/2012-03 study

Annals of oncology, 2016-10, Vol.27, p.vi46-vi46

2016

Volltextzugriff (PDF)

1 – 25 von 39

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieAnnals Of Oncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(39)
Mit Volltextzugriff
(39)

Publikationsform

Artikel
(39)

Sprache

Englisch
(39)

Erscheinungsjahr

n.n

Kollektion

Zeitschrift / Serie

Annals Of Oncology : Official Journal Of The European Society For Medical Oncology
(1)

Menü

Weitere Dienste

Einstellungen

ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer

Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer

Clinical impact of circulating tumor RAS and BRAF mutation dynamics in metastatic colorectal cancer patients treated with first-line chemotherapy plus anti-EGFR therapy: Combined analysis of two prospective clinical trials

MiR-29c downregulation contributes to metastatic progression in colorectal cancer

SET overexpression promotes colorectal cancer progression and determines poor outcome in patients with localized disease

Prospective biomarker study in advanced RAS wild-type colorectal cancer: POSIBA trial

45P In silico transcriptomic mapping of Notch biological pathway in luminal breast cancer

Comorbidities (CM) and potential impact in outcomes of advanced colorectal cancer patients (ACC) in Argentina: EVIREPRO real life program - Trial in progress

Lack of efficiency of precision oncology with target-based investigational treatments for patients in early phase clinical trials based on pre-screened molecular alterations

Involvement of miR-99a in resistance to chemotherapy in triple-negative breast cancer

Role of miR-449 family on doxorubicin-based chemotherapy response in triple-negative breast cancer

Micro-RNA 33b inhibits breast cancer migration and invasion through regulating epithelial-mesenchymal transition in HER2 positive breast cancer cell lines

195P A prognostic signature based on two-miRNA and pathological data in early-stage HER2+ breast cancer patients

Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxel

LBA19 GEICAM/2014-12 (FLIPPER) study: First analysis from a randomized phase II trial of fulvestrant (F)/palbociclib (P) versus (vs) F/placebo (PL) as first-line therapy in postmenopausal women with HR (hormone receptor)+/HER2– endocrine sensitive advanced breast cancer (ABC)

319P - The role of AXL as mechanism of resistance to trastuzumab and a prognostic factor in breast cancer HER2 positive: A translational approach

The role of AXL as mechanism of resistance to trastuzumab and a prognostic factor in breast cancer HER2 positive: A translational approach

First prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis

Prospective evaluation of BRAF, PI3K and PTEN as predictive and prognostic biomarkers in first-line advanced KRAS wild-type colorectal cancer treated with FOLFOX or FOLFIRI plus bi-weekly cetuximab. GEMCAD 10-02

AXL as a potential primary and secondary trastuzumab resistance mechanism in breast cancer cells with HER2 overexpression

A phase I study of sonidegib (S) in combination with docetaxel (D) in patients (pts) with triple negative (TN) advanced breast cancer (ABC): GEICAM/2012-12 (EDALINE study)

MicroRNA-31 overexpression is able to predict pathological response and outcome in locally advanced rectal cancer

A phase II trial of dasatinib (D) in combination with trastuzumab (T) and paclitaxel (P) in the first line treatment of HER2 positive metastatic breast cancer (MBC) patients (pts): GEICAM/2010-04

Analysis of stroma and immune-related gene expression patterns during breast cancer (BC) progression

Gestational breast cancer: distinctive molecular and clinico-epidemiological features. GEICAM/2012-03 study

Aktive Filter

Suchergebnisse filtern